Wilson Sonsini Goodrich & Rosati acted as the lead international counsel to WuXi AppTec in the public offering and related restructuring.
WuXi AppTec Co., Ltd. (Stock Code: 603259), a leading global pharmaceutical and medical device open-access capability and technology platform company, executed the listing of its initial public offering of 104,198,600 shares of common stock at a public offering price of RMB21.60 per share. Proceeds from the IPO will be used to build and expand its R&D facilities in China, further strengthening its capabilities and capacities to better serve global customers and partners.
WuXi AppTec, headquartered in Shanghai, is now operating globally with 26 sites and branch offices in China, the United States, Germany, UK, Japan, Korea and Israel. The Company’s integrated R&D, manufacturing and testing platform for small molecules, cell and gene therapies, and medical devices is supporting over 3,000 customers and partners around the world. WuXi AppTec, led by Li Ge, Hu Zhengguo and Liu Xiaozhong, in 2017 recorded $1.26 Billion Revenues.
WSGR advised WuXi AppTec with Weiheng Chen (Picture), Jie Zhu, Linyan (Jill) Sheng, Chunbei (Alice) Li, Kun (Peter) Chen, Draco Ng, Jingyi Yuan, Barry Taylor, Yingting Zhang and Jennifer Gu.
Involved fees earner: Weiheng Chen – Wilson Sonsini Goodrich & Rosati; Jie Zhu – Wilson Sonsini Goodrich & Rosati; Jill Sheng – Wilson Sonsini Goodrich & Rosati; Alice Li – Wilson Sonsini Goodrich & Rosati; Peter Chen – Wilson Sonsini Goodrich & Rosati; Barry Taylor – Wilson Sonsini Goodrich & Rosati; Yingting Zhang – Wilson Sonsini Goodrich & Rosati; Draco Ng – Wilson Sonsini Goodrich & Rosati;
Law Firms: Wilson Sonsini Goodrich & Rosati;
Clients: WuXi AppTec Co. Ltd.;